XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning Balance at Dec. 31, 2020 $ (63,909) $ 125,160 $ 3 $ 2,616 $ 8 $ (66,536)
Beginning Balance (in shares) at Dec. 31, 2020   179,519,032 2,585,789      
Issuance of Series B convertible preferred stock, net of issuance costs of $241   $ 93,759        
Issuance of Series B convertible preferred stock, net of issuance costs (in shares)   77,163,022        
Vesting of restricted common stock (in shares)     134,409      
Exercise of stock options 72     72    
Exercise of stock options (in shares)     48,745      
Unrealized loss on available-for-sale securities (1)       (1)  
Stock-based compensation 670     670    
Net loss (13,263)         (13,263)
Ending Balance at Mar. 31, 2021 (76,431) $ 218,919 $ 3 3,358 7 (79,799)
Ending balance (in shares) at Mar. 31, 2021   256,682,054 2,768,943      
Beginning Balance at Dec. 31, 2020 (63,909) $ 125,160 $ 3 2,616 8 (66,536)
Beginning Balance (in shares) at Dec. 31, 2020   179,519,032 2,585,789      
Conversion of convertible preferred stock to common stock upon closing of initial public offering 218,919          
Issuance of common stock from initial public offering, net of issuance costs of $25,098 (32,490)          
Net loss (66,228)          
Ending Balance at Jun. 30, 2021 405,396   $ 48 538,109 3 (132,764)
Ending balance (in shares) at Jun. 30, 2021     47,946,996      
Beginning Balance at Mar. 31, 2021 (76,431) $ 218,919 $ 3 3,358 7 (79,799)
Beginning Balance (in shares) at Mar. 31, 2021   256,682,054 2,768,943      
Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)   (256,682,054) 27,720,923      
Issuance of common stock from initial public offering, net of issuance costs of $25,098 281,584   $ 16 281,568    
Issuance of common stock from initial public offering, net of issuance costs (in shares)     16,141,157      
Issuance of common stock to licensor institutions 32,490   $ 1 32,489    
Issuance of common stock to licensor institutions (in shares)     878,098      
Vesting of restricted common stock (in shares)     134,408      
Exercise of stock options 452     452    
Exercise of stock options (in shares)     303,467      
Unrealized loss on available-for-sale securities (4)       (4)  
Stock-based compensation 1,351     1,351    
Net loss (52,965)         (52,965)
Ending Balance at Jun. 30, 2021 405,396   $ 48 538,109 3 (132,764)
Ending balance (in shares) at Jun. 30, 2021     47,946,996      
Conversion of convertible preferred stock to common stock upon closing of initial public offering 218,919 $ (218,919) $ 28 218,891    
Beginning Balance at Dec. 31, 2021 $ 357,352   $ 49 544,381 (228) (186,850)
Beginning Balance (in shares) at Dec. 31, 2021 48,511,735   48,511,735      
Exercise of stock options $ 505     505    
Exercise of stock options (in shares)     143,506      
Unrealized loss on available-for-sale securities (504)       (504)  
Stock-based compensation 4,203     4,203    
Net loss (30,166)         (30,166)
Ending Balance at Mar. 31, 2022 331,390   $ 49 549,089 (732) (217,016)
Ending balance (in shares) at Mar. 31, 2022     48,655,241      
Beginning Balance at Dec. 31, 2021 $ 357,352   $ 49 544,381 (228) (186,850)
Beginning Balance (in shares) at Dec. 31, 2021 48,511,735   48,511,735      
Conversion of convertible preferred stock to common stock upon closing of initial public offering          
Exercise of stock options (in shares) 172,699          
Net loss $ (71,112)          
Ending Balance at Jun. 30, 2022 $ 296,333   $ 49 555,184 (938) (257,962)
Ending balance (in shares) at Jun. 30, 2022 48,709,652   48,709,652      
Beginning Balance at Mar. 31, 2022 $ 331,390   $ 49 549,089 (732) (217,016)
Beginning Balance (in shares) at Mar. 31, 2022     48,655,241      
Exercise of stock options 120     120    
Exercise of stock options (in shares)     29,193      
Issuance of common stock under Employee Stock Purchase Plan, shares     25,218      
Issuance of common stock under Employee Stock Purchase Plan 325     325    
Unrealized loss on available-for-sale securities (206)       (206)  
Stock-based compensation 5,650     5,650    
Net loss (40,946)         (40,946)
Ending Balance at Jun. 30, 2022 $ 296,333   $ 49 $ 555,184 $ (938) $ (257,962)
Ending balance (in shares) at Jun. 30, 2022 48,709,652   48,709,652